Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

BACKGROUND: Empagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Park, Sin-Hee, Farooq, Muhammad Akmal, Gaertner, Sébastien, Bruckert, Christophe, Qureshi, Abdul Wahid, Lee, Hyun-Ho, Benrahla, Djamel, Pollet, Brigitte, Stephan, Dominique, Ohlmann, Patrick, Lessinger, Jean-Marc, Mayoux, Eric, Auger, Cyril, Morel, Olivier, Schini-Kerth, Valérie B.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7026972/
https://ncbi.nlm.nih.gov/pubmed/32070346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-00997-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados